This is a routine M&A communication with no new financial or deal-structure information. The preclinical data is promotional and does not change the merger timeline or terms. Monitor for the S-4 proxy statement/prospectus and stockholder vote for the next material catalyst.
Price Chart
Executive Summary
Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sachs Obesity Forum. The filing reiterates the pending merger with Pulmatrix (expected Q3 2026) and highlights PTC-2105's potential in body composition and survival. No new financial terms or deal changes were disclosed.
Key Financial Metrics
Key Facts
- Eos SENOLYTIX presented preclinical data for PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum on June 5, 2026.
- PTC-2105 demonstrated reductions in fat mass greater than GLP-1s, gains in lean mass, and improved physical function in preclinical studies.
- In naturally aged mice, 40% of the PTC-2105 25 mg/kg cohort remained alive at 146 weeks vs. 100% mortality in controls by 137 weeks (p=0.0142).
- The merger between Pulmatrix and Eos was announced March 26, 2026, expected to close in Q3 2026, with combined company trading under ticker MTXL.
- No changes to merger terms, deal value, or timeline were disclosed in this filing.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to clinical outcomes.
- Merger closing is subject to stockholder approval and customary conditions.
- Combined company needs merger-associated financings to support pipeline advancement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index-headers.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416.txt | 0001493152-26-027416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | S-4/A | $1.40 $1.45 | ▼ −3.58% | ▼ −4.70% | $1.57 (−12.54%) |
Aug 13, 2026 7w ago | 8-K | $1.51 $1.50 | ▼ −0.66% | ▲ +1.30% | $1.57 (+3.97%) |
Aug 13, 2026 7w ago | Press Release | $1.51 $1.50 | ▲ +0.66% | ▼ −1.30% | $1.57 (−3.97%) |
Aug 7, 2026 7w ago | S-3/A | $1.57 $1.56 | ▲ +0.64% | ▲ +0.59% | $1.57 (−0.00%) |
Jun 16, 2026 15w ago | 10-K/A | $1.50 $1.53 | ▲ +2.00% | ▲ +3.04% | $1.57 (+4.67%) |
Jun 5, 2026 17w ago | 425 | $1.33 $1.40 | ▲ +5.26% | ▲ +4.69% | $1.57 (+18.05%) |
Jun 4, 2026 17w ago | S-3 | $1.32 $1.38 | ▼ −4.55% | ▼ −7.10% | $1.57 (−18.94%) |
May 15, 2026 20w ago | 8-K | $1.25 $1.34 | ▲ +7.20% | ▲ +6.24% | $1.57 (+25.60%) |
Apr 21, 2026 23w ago | 8-K | $1.38 $1.28 | ▼ −7.25% | ▼ −8.33% | $1.57 (+13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access